Yunzhao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yunzhao Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Ziheng Wang
Faculty of Health Sciences, University of Macau
3 shared publicationsJinling Chen
Department of Pathogen Biology, School of Medicine, Nantong University, Nantong 226001, Jiangsu, People's Republic of China
2 shared publications- Jinling Chen
Department of Pathogen Biology, Medical School of Nantong University, Nantong, People’s Republic of China
2 shared publications Shiqi Ren
Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China
2 shared publicationsWenliang Ge
Department of Pediatric Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
2 shared publicationsYue Zhong
Department of Pathogen Biology, School of Medicine, Nantong University, Nantong, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 282, 109016
The role of MyD88 in the nervous system: Neuronal functions, implications in neurological diseases, and therapeutic potential
- 11 March 2026
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 282, 109016
Open AccessThe role of MyD88 in the nervous system: Neuronal functions, implications in neurological diseases, and therapeutic potential
- 28 January 2025
- Published by Elsevier in Gastroenterology
- Vol. 168 (5) , 1037-1038
Machine Learning in Gastrointestinal Bleeding Risk Stratification: Promising Advances and Remaining Challenges
- 28 January 2025
- Published by Elsevier in Gastroenterology
- Vol. 168 (5) , 1037-1038
Machine Learning in Gastrointestinal Bleeding Risk Stratification: Promising Advances and Remaining Challenges
- Open Access
- 17 April 2024
- Published by Springer Nature in Parasites & Vectors
- Vol. 17 (1) , 1-17
Inhibition of Foxp3 expression in the placenta of mice infected intraperitoneally by toxoplasma gondii tachyzoites: insights into the PPARγ/miR-7b-5p/Sp1 signaling pathway
Background: Toxoplasma gondii, an obligate intracellular parasitic protozoa, infects approximately 30% of the global population. Contracting T. gondii at the primary infection of the mother can result in neonatal microcephaly, chorioretinitis, hydrocephalus, or mortality. Our previous study indicated that pregnant mice infected with T. gondii displayed a decrease in both the number and the suppressive ability of regulatory T cells, accompanied by the reduced Forkhead box P3 (Foxp3). Numerous studies have proved that microRNAs (miRNAs) are implicated in T. gondii infection, but there is meager evidence on the relationship between alterations of miRNAs and downregulation of Foxp3 induced by T. gondii. Methods: Quantitative reverse transcription polymerase chain reaction was utilized to detect the transcriptions of miRNAs and Foxp3. Protein blotting and immunofluorescence were used to detect the expressions of Foxp3 and related transcription factors. The structure of mouse placenta was observed by hematoxylin and eosin (HE) staining. To examine the activity of miR-7b promoter and whether miR-7b-5p targets Sp1 to suppress Foxp3 expression, we constructed recombinant plasmids containing the full-length/truncated/mutant miR-7b promoter sequence or wildtype/mutant of Sp1 3' untranslated region (3' UTR) to detect the fluorescence activity in EL4 cells. Results: In T. gondii-infected mice, miR-7b transcription was significantly elevated, while Foxp3 expression was decreased in the placenta. In vitro, miR-7b mimics downregulated Foxp3 expression, whereas its inhibitors significantly upregulated Foxp3 expression. miR-7b promoter activity was elevated upon the stimulation of T. gondii antigens, which was mitigated by co-transfection of mutant miR-7b promoter lacking peroxisome proliferator-activated receptor γ (PPARγ) target sites. Additionally, miR-7b mimics diminished Sp1 expression, while miR-7b inhibitors elevated its expression. miR-7b mimics deceased the fluorescence activity of Sp1 3' untranslated region (3' UTR), but it failed to impact the fluorescence activity upon the co-transfection of mutant Sp1 3' UTR lacking miR-7b target site. Conclusions: T. gondii infection and antigens promote miR-7b transcription but inhibit Foxp3 protein and gene levels. T. gondii antigens promote miR-7b promoter activity by a PPARγ-dependent mechanism. miR-7b directly binds to Sp1 3' UTR to repress Sp1 expression. Understanding the regulatory functions by which T. gondii-induced miR-7b suppresses Foxp3 expression can provide new perspectives for the possible therapeutic avenue of T. gondii-induced adverse pregnancy outcomes. Graphical
- 17 April 2024
- Published by Springer Nature in Parasites & Vectors
- Vol. 17 (1) , 1-17
Open AccessInhibition of Foxp3 expression in the placenta of mice infected intraperitoneally by toxoplasma gondii tachyzoites: insights into the PPARγ/miR-7b-5p/Sp1 signaling pathway
Background: Toxoplasma gondii, an obligate intracellular parasitic protozoa, infects approximately 30% of the global population. Contracting T. gondii at the primary infection of the mother can result in neonatal microcephaly, chorioretinitis, hydrocephalus, or mortality. Our previous study indicated that pregnant mice infected with T. gondii displayed a decrease in both the number and the suppressive ability of regulatory T cells, accompanied by the reduced Forkhead box P3 (Foxp3). Numerous studies have proved that microRNAs (miRNAs) are implicated in T. gondii infection, but there is meager evidence on the relationship between alterations of miRNAs and downregulation of Foxp3 induced by T. gondii. Methods: Quantitative reverse transcription polymerase chain reaction was utilized to detect the transcriptions of miRNAs and Foxp3. Protein blotting and immunofluorescence were used to detect the expressions of Foxp3 and related transcription factors. The structure of mouse placenta was observed by hematoxylin and eosin (HE) staining. To examine the activity of miR-7b promoter and whether miR-7b-5p targets Sp1 to suppress Foxp3 expression, we constructed recombinant plasmids containing the full-length/truncated/mutant miR-7b promoter sequence or wildtype/mutant of Sp1 3' untranslated region (3' UTR) to detect the fluorescence activity in EL4 cells. Results: In T. gondii-infected mice, miR-7b transcription was significantly elevated, while Foxp3 expression was decreased in the placenta. In vitro, miR-7b mimics downregulated Foxp3 expression, whereas its inhibitors significantly upregulated Foxp3 expression. miR-7b promoter activity was elevated upon the stimulation of T. gondii antigens, which was mitigated by co-transfection of mutant miR-7b promoter lacking peroxisome proliferator-activated receptor γ (PPARγ) target sites. Additionally, miR-7b mimics diminished Sp1 expression, while miR-7b inhibitors elevated its expression. miR-7b mimics deceased the fluorescence activity of Sp1 3' untranslated region (3' UTR), but it failed to impact the fluorescence activity upon the co-transfection of mutant Sp1 3' UTR lacking miR-7b target site. Conclusions: T. gondii infection and antigens promote miR-7b transcription but inhibit Foxp3 protein and gene levels. T. gondii antigens promote miR-7b promoter activity by a PPARγ-dependent mechanism. miR-7b directly binds to Sp1 3' UTR to repress Sp1 expression. Understanding the regulatory functions by which T. gondii-induced miR-7b suppresses Foxp3 expression can provide new perspectives for the possible therapeutic avenue of T. gondii-induced adverse pregnancy outcomes. Graphical
- Open Access
- 31 July 2023
- Published by Springer Nature in Research Square
MYO1E correlates with immune cells infiltration and PD-1/PD-L1 expression in ovarian cancer
Objective MYO1E is an actin-dependent ATPase that controls tumor development and promotes tumor cell migration and invasion. However, it remains unclear about the relationship between MYO1E and ovarian cancer's clinicopathological characteristics, tumor-infiltrating immune cells, and PD-1/PD-L1. Methods Using bioinformatics tools and multiplex immunohistochemistry, we investigated the relationship between MYO1E expression and clinicopathological features of ovarian cancer. Further, we analyzed the relevance between MYO1E expression, tumor-infiltrating immune cells, and PD-1/PD-L1 in ovarian cancer. Results There is overexpression of MYO1E mRNA and protein in ovarian cancer compared to the normal ovary and fallopian tube tissue. MYO1E expression is associated with an unfavorable ovarian cancer prognosis in univariate and multivariate Cox regression analyses. Furthermore, we discovered that MYO1E was associated with neutrophils, macrophages, and PD-1/PD-L1 in the ovarian cancer microenvironment. Conclusions Our studies confirmed that MYO1E acts as a predictive marker and has potential implications for immunity therapy in ovarian cancer.
- 31 July 2023
- Published by Springer Nature in Research Square
Open AccessMYO1E correlates with immune cells infiltration and PD-1/PD-L1 expression in ovarian cancer
Objective MYO1E is an actin-dependent ATPase that controls tumor development and promotes tumor cell migration and invasion. However, it remains unclear about the relationship between MYO1E and ovarian cancer's clinicopathological characteristics, tumor-infiltrating immune cells, and PD-1/PD-L1. Methods Using bioinformatics tools and multiplex immunohistochemistry, we investigated the relationship between MYO1E expression and clinicopathological features of ovarian cancer. Further, we analyzed the relevance between MYO1E expression, tumor-infiltrating immune cells, and PD-1/PD-L1 in ovarian cancer. Results There is overexpression of MYO1E mRNA and protein in ovarian cancer compared to the normal ovary and fallopian tube tissue. MYO1E expression is associated with an unfavorable ovarian cancer prognosis in univariate and multivariate Cox regression analyses. Furthermore, we discovered that MYO1E was associated with neutrophils, macrophages, and PD-1/PD-L1 in the ovarian cancer microenvironment. Conclusions Our studies confirmed that MYO1E acts as a predictive marker and has potential implications for immunity therapy in ovarian cancer.
- Open Access
- 13 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 971017
Single-cell sequencing of brain tissues reveal the central nervous system’s susceptibility to SARS-CoV-2 and the drug
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the current COVID-19 pandemic, resulting in a public health crisis that required immediate action. The SARS-CoV-2 virus enters human cells via three receptors, namely cathepsin, angiotensin-converting enzyme 2 (ACE2) and SARS-CoV receptors. Cathepsin destroys the spike protein (S protein), thereby allowing the entry of viral nucleic acid into human host cells.Methods: Utilizing single-cell transcriptome analysis of brain tissues, the vulnerability of the central nervous system to infection with SARS-CoV-2 in humans was investigated.Results: ACE2 is mainly expressed in endothelial cells, with the highest levels found in ageing endothelial cells. Drug prediction suggests that (-)-catechin reduces the effects of COVID-19 on the nervous system. Immunohistochemistry analysis showed that ACE2 was mainly expressed in cerebral vessels. Immunofluroscenceresults showed the co-expression of CD31 and ACE2 in human tissues. Western blot further showed that ACE2 expression was higher in old rats than in young rats.Conclusion: This study provides insight into the mechanism of SARS-CoV-2 brain invasion. Accordingly, patients with neurological symptoms who are infected with SARS-CoV-2 should be given individualised care.
- 13 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 971017
Open AccessSingle-cell sequencing of brain tissues reveal the central nervous system’s susceptibility to SARS-CoV-2 and the drug
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the current COVID-19 pandemic, resulting in a public health crisis that required immediate action. The SARS-CoV-2 virus enters human cells via three receptors, namely cathepsin, angiotensin-converting enzyme 2 (ACE2) and SARS-CoV receptors. Cathepsin destroys the spike protein (S protein), thereby allowing the entry of viral nucleic acid into human host cells.Methods: Utilizing single-cell transcriptome analysis of brain tissues, the vulnerability of the central nervous system to infection with SARS-CoV-2 in humans was investigated.Results: ACE2 is mainly expressed in endothelial cells, with the highest levels found in ageing endothelial cells. Drug prediction suggests that (-)-catechin reduces the effects of COVID-19 on the nervous system. Immunohistochemistry analysis showed that ACE2 was mainly expressed in cerebral vessels. Immunofluroscenceresults showed the co-expression of CD31 and ACE2 in human tissues. Western blot further showed that ACE2 expression was higher in old rats than in young rats.Conclusion: This study provides insight into the mechanism of SARS-CoV-2 brain invasion. Accordingly, patients with neurological symptoms who are infected with SARS-CoV-2 should be given individualised care.
- 11 March 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 107, 108648
Toxoplasma gondii promotes microRNA-34a to inhibit Foxp3 expression in adverse outcomes of pregnancy in mice
- 11 March 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 107, 108648
Toxoplasma gondii promotes microRNA-34a to inhibit Foxp3 expression in adverse outcomes of pregnancy in mice
- Open Access
- 1 January 2022
- Published by Tech Science Press in BIOCELL
- Vol. 46 (3) , 689-697
KIAA1199 induces advanced biological behavior and development of ovarian cancer through activation of the IL-6/STAT3 pathway
Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC cells, and the expression of KIAA1199, STAT3 and p-STAT3 increased after IL-6 stimulation. These results could show that KIAA1199 is transcriptionally activated by IL6/STAT3 pathway, thereby accelerating the deterioration of EOC. KIAA1199 could also be used as a poor prognosis factor and potential target in treatment.
- 1 January 2022
- Published by Tech Science Press in BIOCELL
- Vol. 46 (3) , 689-697
Open AccessKIAA1199 induces advanced biological behavior and development of ovarian cancer through activation of the IL-6/STAT3 pathway
Recently, abnormal expression of KIAA1199 has been detected in Epithelial Ovarian Cancer (EOC). However, the underlined anti-ovarian cancer mechanism of KIAA1199 remains to be enlightened. In our study, we performed to elucidate the effects of KIAA1199 on the advanced biological behavior of EOC cells through activation of the IL-6/STAT3 pathway. Confirmed by immunohistochemistry, KIAA1199 was highly expressed in ovarian borderline and malignant epithelial tumors. A retrospective analysis found that EOC patients with low expression of KIAA1199 had a significantly higher 5-year survival rate than those with high expression. Mechanistically, IL-6 was used to stimulate EOC cells, and the expression of KIAA1199, STAT3 and p-STAT3 increased after IL-6 stimulation. These results could show that KIAA1199 is transcriptionally activated by IL6/STAT3 pathway, thereby accelerating the deterioration of EOC. KIAA1199 could also be used as a poor prognosis factor and potential target in treatment.
- Open Access
- 31 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Development of a Prognostic Model for Ovarian Cancer Patients Based on Novel Immune Microenvironment Related Genes
Ovarian cancer (OV) has become the most lethal gynecological cancer. However, its treatment methods and staging system are far from ideal. In the present study, taking the advantage of large-scale public cohorts, we extracted a list of immune-related prognostic genes that differentially expressed in tumor and normal ovarian tissues. Importantly, an individualized immune-related gene based prognostic model (IPM) for OV patients were developed. Furthermore, we validated our IPM in Gene Expression Omnibus (GEO) repository and compared the immune landscape and pathways between high-risk and low-risk groups. The results of our study can serve as an important model to identify the immune subset of patients and has potential for use in immune therapeutic selection and patient management.
- 31 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessDevelopment of a Prognostic Model for Ovarian Cancer Patients Based on Novel Immune Microenvironment Related Genes
Ovarian cancer (OV) has become the most lethal gynecological cancer. However, its treatment methods and staging system are far from ideal. In the present study, taking the advantage of large-scale public cohorts, we extracted a list of immune-related prognostic genes that differentially expressed in tumor and normal ovarian tissues. Importantly, an individualized immune-related gene based prognostic model (IPM) for OV patients were developed. Furthermore, we validated our IPM in Gene Expression Omnibus (GEO) repository and compared the immune landscape and pathways between high-risk and low-risk groups. The results of our study can serve as an important model to identify the immune subset of patients and has potential for use in immune therapeutic selection and patient management.
- Open Access
- 1 January 2020
- Published by Tech Science Press in BIOCELL
- Vol. 44 (4) , 597-605
Microenvironment and related genes predict outcomes of patients with cervical cancer: evidence from TCGA and bioinformatic analysis
Cervical cancer (CESC) is one of the most common cancers and affects the female genital tract. Consistent HPV infection status has been determined to be a vital cause of tumorigenesis. HPV infection may induce changes to the immune system and limit the host’s immune response. Immunotherapy is therefore essential to improving the overall survival of both locally advanced and recurrent CESC patients. Using 304 relevant samples from TCGA, we assessed immune cell function in CESC patients to better understand the status of both tumor micro-environment cells and immune cells in CESC. Functional enrichment analysis, pathway enrichment analysis, and PPI network construction were performed to explore the differentially expressed genes (DEGs). The analysis identified 425 DEGs, which included 295 up-regulated genes and 130 down-regulated genes. We established that upregulation of CCL5 was correlated with significantly better survival, meaning that CCL5 expression could serve as a novel prognostic biomarker for CESC patients. We further focused on CCL5 as a hub gene in CESC, as it had significant correlations with increased numbers of several types of immune cells. Cell-type fractions of M1 macrophages were significantly higher in the high-immune-scores group, which was associated with better overall survival. Finally, we concluded that CCL5 is a promising prognostic biomarker for CESC, as well as a novel chemotherapeutic target.
- 1 January 2020
- Published by Tech Science Press in BIOCELL
- Vol. 44 (4) , 597-605
Open AccessMicroenvironment and related genes predict outcomes of patients with cervical cancer: evidence from TCGA and bioinformatic analysis
Cervical cancer (CESC) is one of the most common cancers and affects the female genital tract. Consistent HPV infection status has been determined to be a vital cause of tumorigenesis. HPV infection may induce changes to the immune system and limit the host’s immune response. Immunotherapy is therefore essential to improving the overall survival of both locally advanced and recurrent CESC patients. Using 304 relevant samples from TCGA, we assessed immune cell function in CESC patients to better understand the status of both tumor micro-environment cells and immune cells in CESC. Functional enrichment analysis, pathway enrichment analysis, and PPI network construction were performed to explore the differentially expressed genes (DEGs). The analysis identified 425 DEGs, which included 295 up-regulated genes and 130 down-regulated genes. We established that upregulation of CCL5 was correlated with significantly better survival, meaning that CCL5 expression could serve as a novel prognostic biomarker for CESC patients. We further focused on CCL5 as a hub gene in CESC, as it had significant correlations with increased numbers of several types of immune cells. Cell-type fractions of M1 macrophages were significantly higher in the high-immune-scores group, which was associated with better overall survival. Finally, we concluded that CCL5 is a promising prognostic biomarker for CESC, as well as a novel chemotherapeutic target.